Skip to main content
Home
Zeitschriften
Zeitungen
Podcast
Gesundheitspolitik
Praxis
Allerlei
Jobs
Fachgebiete
Allgemeinmedizin Anästhesiologie & Intensivmedizin Apotheke Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kinder & Jugendheilkunde Neurologie & Psychiatrie Orthopädie & Unfallchirurgie Pflege Urologie Zahnmedizin
Subfächer Innere Medizin
Diabetologie Gastroenterologie Infektiologie Kardiologie Onkologie und Hämatologie Pneumologie Rheumatologie
Fortbildungen
Überblick Fortbildungen DFP-Literaturstudium-Artikel DFP-Webcast Fortbildungen DFP-Podcasts
Erweiterte Suche
Anmelden
nach oben
memo - Magazine of European Medical Oncology
Erschienen in:

01.09.2012 | short review

Follow-up care for head and neck cancer patients

verfasst von: Markus Hambek, MD

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 3/2012

Einloggen, um Zugang zu erhalten

Abstract

The major issue of the follow-up period is the early detection of recurrent and second tumors. Beside this, a team of specialized physicians and nurses should take care of the patient in terms of quality of life and rehabilitation. Follow-up appointments therefore should include physical examination with office-based endoscopy, ultrasonography, radiological imaging, dental evaluation, blood testing for TSH and EBV, voice and swallowing evaluation, pain management, QoL-Questionnaire, nutritional and psychological evaluation and treatment. Follow-up care should be managed by a multidisciplinary group of specialized and certified health care professionals in order to achieve the best results and outcome for the patients.
Vorheriger Artikel New drugs for head and neck cancer
Nächster Artikel Sorafenib in thyroid cancer—a retrospective case series
Literatur
1.
NCCN Guidelines™ Version 2.2011. Head and neck cancers. Online at nccn.org.
2.
Grégoire V, Lefebvre JL, Licitra L, Felip E. EHNS-ESMO-ESTRO Guidelines Working Group. Squamous cell carcinoma of the head and neck: EHNS-ESMO-ESTRO clinical practice guidelines for diagnosis, treatment, and follow-up. Ann Oncol. 2010;21(Suppl 5):v184–6 (PubMed PMID: 20555077).
3.
Deutsche Krebsgesellschaft. Kurzgefasste interdisziplinäre Leitlinien. Empfehlungen zur Diagnostik und Therapie maligner Erkrankungen. Verlag Zuckschwerdt; 2008.
4.
EORTC QLQ HN 35, Copyright 1995 EORTC quality of life Study Group, version 1.0.
5.
AWMF Leitlinie S1 Hals: Zustand nach Tumor-OP v. 11/2009. Online at www.awmf.org.
6.
Al-Ibraheem A, Buck A, Krause BJ, Scheidhauer K, Schwaiger M. Clinical applications of FDG PET and PET/CT in head and neck cancer. J Oncol. 2009;2009:208725 (PubMed PMID: 19707528; PubMed Central PMCID:PMC2730473).PubMedCrossRef
7.
Klabbers BM, Lammertsma AA, Slotman BJ. The value of positron emission tomography for monitoring response to radiotherapy in head and neck cancer. Mol Imaging Biol. 2003;5(4):257–70 (Review. PubMed PMID: 14499141).PubMedCrossRef
8.
Ryan WR, Fee WE Jr, Le Q-T, Pinto HA. Positronemission tomography for surveillance of head and neck cancer. Laryngoscope. 2005;115(4):645–50.PubMedCrossRef
9.
Abgral R, Querellou S, Potard G, et al. Does 18F-FDG PET/CT improve the detection of posttreatment recurrence of head and neck squamous cell carcinoma in patients negative for disease on clinical follow-up? J Nucl Med. 2009;50(1):24–9.PubMedCrossRef
10.
Wang Y-F, Liu R-S, Chu P-Y, et al. Positron emission tomography in surveillance of head and neck squamous cell carcinoma after definitive chemoradiotherapy. Head Neck. 2009;31(4):442–51.PubMedCrossRef
11.
Cermik TF, Mavi A, Acikgoz G, Houseni M, Dadparvar S, Alavi A. FDG PET in detecting primary and recurrent malignant salivary gland tumors. Clin Nucl Med. 2007;32(4):286–91.PubMedCrossRef
12.
Alvarez Perez RM, Borrego Dorado I, Ruiz Franco-Baux JV, Vazquez Albertino RJ. Evaluation of efficacy and clinical impact of positron emission tomography with 18F fluoro-deoxyglucose in patients with suspicion of recurrent head and neck cancer or distant metastases. Rev Espanola deMedicina Nucl. 2007;26(1):30–9.CrossRef
13.
Salaun PY, Abgral R, Querellou S, et al. Does 18fluorofluorodeoxyglucose positron emission tomography improve recurrence detection in patients treated for head and neck squamous cell carcinoma with negative clinical follow-up? Head Neck. 2007;29(12):1115–20.PubMedCrossRef
14.
Goerres GW, Schmid DT, Bandhauer F, et al. Positron emission tomography in the early follow-up of advanced head and neck cancer. Arch Otolaryngol. 2004;130(1):105–9.CrossRef
15.
Kubota K, Yokoyama J, Yamaguchi K, et al. FDGPET delayed imaging for the detection of head and neck cancer recurrence after radio-chemotherapy: comparison with MRI/CT. Eur J Nucl Med Mol Imaging. 2004;31(4):590–5.PubMedCrossRef
16.
Welkoborsky HJ. Ultrasound usage in the head and neck surgeon’s office. Curr Opin Otolaryngol Head Neck Surg. 2009;17(2):116–21 (PubMed PMID: 19363347).PubMedCrossRef
17.
Yoon DY, Hwang HS, Chang SK, et al. CT, MR, US, (18)-F-FDG PET/CT, and their combined use for the assessment of cervical lymph node metastases in squamous cell carcinoma of the head and neck. Eur Radiol. 2008;19:634–42.PubMedCrossRef
18.
Roper B, Nuse N, Busch R, et al. Tissue characterization of locoregionally advanced head-and-neck squamous cell carcinoma (HNSCC) using quantified ultrasonography: a prospective phase II study on prognostic relevance. Radiother Oncol. 2007;85:48–57.PubMedCrossRef
19.
DeVita, VT, Hellman, S, Rosenberg, SA. Cancer: principles and practice of oncology. 8th Revised edn. Lippincott Williams & Wilkins; 2008.
20.
Logeman, JA. Evaluation and treatment of swallowing disorders. 2nd edn., Vol. 13. Austin: PRO-ED; 1998.
21.
Dodds WJ, Stewart ET, Logemann JA. Physiology and radiology of the normal oral and pharyngeal phases of swallowing (comment). Am J Roentgenol. 1990;154(5):953.
22.
Recommendations of the American Speech-Language-Hearing Association. Available online at www.asha.org.
23.
Brizel DM, Wasserman TH, Henke M, Strnad V, Rudat V, Monnier A, et al. Phase III randomized trial of amifostine as a radioprotector in head and neck cancer. J Clin Oncol. 2000;18(19):3339–45.PubMed
24.
Logan RM, Stringer AM, Bowen JM, Yeoh AS, Gibson RJ, Sonis ST, et al. The role of pro-inflammatory cytokines in cancer treatment-induced alimentary tract mucositis: pathobiology, animal models, and cytotoxic drugs. Cancer Treat Rev. 2007;33(5):448–60.PubMedCrossRef
Metadaten
Titel
Follow-up care for head and neck cancer patients
verfasst von
Markus Hambek, MD
Publikationsdatum
01.09.2012
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 3/2012
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-012-0017-0

Weitere Artikel der Ausgabe 3/2012

The End-of-Life in patients with glioma and their families

  • short review

Sorafenib in thyroid cancer—a retrospective case series

  • case report

ASH 2011—current developments in AML

  • short review

News from the Neuro-Oncology front

  • editorial

Clinically useful biomarkers in neurooncology

  • short review

ASH update 2011: chronic lymphocytic leukemia and indolent lymphoma

  • short review